BridgeBio Pharma Inc
NASDAQ:BBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (29.9), the stock would be worth $77.05 (11% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 27 | $69.71 |
0%
|
| 3-Year Average | 29.9 | $77.05 |
+11%
|
| 5-Year Average | 29.7 | $76.49 |
+10%
|
| Industry Average | 6.7 | $17.36 |
-75%
|
| Country Average | 2.4 | $6.28 |
-91%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$14.1B
|
/ |
Jan 2026
$502.1m
|
= |
|
|
$14.1B
|
/ |
Dec 2026
$951.2m
|
= |
|
|
$14.1B
|
/ |
Dec 2027
$1.7B
|
= |
|
|
$14.1B
|
/ |
Dec 2028
$2.5B
|
= |
|
|
$14.1B
|
/ |
Dec 2029
$3.4B
|
= |
|
|
$14.1B
|
/ |
Dec 2030
$4.1B
|
= |
|
|
$14.1B
|
/ |
Dec 2031
$5B
|
= |
|
|
$14.1B
|
/ |
Dec 2032
$5.5B
|
= |
|
|
$14.1B
|
/ |
Dec 2033
$5.9B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
BridgeBio Pharma Inc
NASDAQ:BBIO
|
13.6B USD | 27 | -18.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | 5.7 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 5 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 5.5 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 9.1 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 5.4 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 11.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 2.7 | 29.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
BridgeBio Pharma Inc
Glance View
BridgeBio Pharma Inc. stands as a compelling figure in the biotechnology sector, driven by its mission to address and rectify genetic diseases at their root. Formed with the belief that breakthrough medicines for genetic disorders could be developed with unprecedented speed and precision, the company focuses on identifying clinically validated genetic pathways. By collaborating with leading researchers and utilizing sophisticated drug development platforms, BridgeBio seeks to rapidly translate genetic insights into medical innovations. The company's distinct approach concentrates on single-gene disorders across various therapeutic areas including oncology, cardiology, dermatology, and neurology. The financial workings of BridgeBio Pharma revolve around its robust pipeline of targeted therapies. Essentially, its revenue model is anchored in developing investigational therapies that hold the potential for lucrative partnerships and licensing deals with larger pharmaceutical entities. As these therapies progress through clinical stages, their valuation—and hence the potential for revenue—significantly increases. BridgeBio also leverages a strategy of creating subsidiary companies for each drug in its pipeline, promoting both focus and accountability. This organizational structure enables efficient capital allocation and innovation while also opening up opportunities for public market offerings and strategic exits, thereby driving the financial engine of BridgeBio.
